Skip to main content

Table 2 Risk ratios of ACR20/50 response rates of tofacitinib vs.40 mg adalimumab at month 3[21] and 6[22]

From: Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

  ACR20 ACR50
Dose of tofacitinib Sample size (tofacitinib, adalimumab) Risk ratio [95% CI] Sample size (tofacitinib, adalimumab) Risk ratio [95% CI]
Month 3     
1 mg bid 54, 53 0.88 [0.52, 1.50] 54, 53 0.59 [0.23, 1.51]
3 mg bid 51, 53 1.09 [0.67, 1.80] 51, 53 1.25 [0.59, 2.63]
5 mg bid 49, 53 1.65 [1.08, 2.53] 49, 53 1.95 [1.00, 3.80]
10 mg bid 61, 53 1.97 [1.32, 2.92] 61, 53 2.35 [1.26, 4.38]
15 mg bid 57, 53 2.01 [1.35, 2.98] 57, 53 2.70 [1.46, 4.98]
Month 6,     
5 mg bid 196, 199 1.09 [0.89, 1.33] N/A N/A
10 mg bid 196: 199 1.11 [0.91, 1.36] N/A N/A
  1. bid twice daily; CI confidence interval; N/A, not applicable.